Daniel E. Singer

Q: What Schools Are Affiliated With Daniel E. Singer

Daniel E. Singer is affiliated with the following schools: Stanford University, University of Pittsburgh, Massachusetts General Hospital, Duke University, Harvard University

Daniel E. Singer's AcademicInfluence.com Rankings

Daniel E. Singer

Philosophy

#4228

World Rank

#6674

Historical Rank

Logic

#1733

World Rank

#2569

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Daniel E. Singer's Degrees

Doctorate Medicine University of California, San Francisco
Masters Public Health University of California, Berkeley

Why Is Daniel E. Singer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daniel E. Singer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. (2001) (6218)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. (2011) (5296)
A prediction rule to identify low-risk patients with community-acquired pneumonia. (1997) (3571)
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. (1990) (1377)
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. (2003) (1256)
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (982)
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. (2013) (966)
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. (1996) (868)
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (789)
Assessing Health‐Related Quality of Life in Patients With Sciatica (1995) (788)
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. (2011) (778)
The clinical information value of the glycosylated hemoglobin assay. (1984) (769)
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. (2002) (752)
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study (2009) (751)
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? (2003) (728)
Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (1999) (627)
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (609)
Long-Term Outcomes of Surgical and Nonsurgical Management of Lumbar Spinal Stenosis: 8 to 10 Year Results from the Maine Lumbar Spine Study (2005) (604)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011) (591)
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. (2004) (587)
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. (2000) (554)
Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation (2004) (554)
Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study (1997) (543)
Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. (2002) (528)
The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation (2009) (516)
Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. (1998) (506)
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. (2007) (500)
Long-Term Outcomes of Surgical and Nonsurgical Management of Sciatica Secondary to a Lumbar Disc Herniation: 10 Year Results from the Maine Lumbar Spine Study (2005) (489)
Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study (2005) (456)
Polypharmacy and medication adherence in patients with type 2 diabetes. (2003) (426)
The unmet health care needs of homeless adults: a national study. (2010) (425)
Surgical and nonsurgical management of lumbar spinal stenosis: four-year outcomes from the maine lumbar spine study. (2000) (425)
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. (2013) (418)
Influence of age on symptoms at presentation in patients with community-acquired pneumonia. (1997) (411)
Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2009) (411)
National patterns in the treatment of smokers by physicians. (1998) (399)
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. (2002) (386)
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. (2016) (360)
Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. (2001) (351)
Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices) (2013) (350)
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF (2012) (335)
Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators (2009) (330)
A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score (2013) (321)
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. (2008) (319)
Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. (1996) (314)
Decreased cognitive function in aging non-insulin-dependent diabetic patients. (1984) (305)
Can Patients Be Anticoagulated After Intracerebral Hemorrhage?: A Decision Analysis (2003) (304)
The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? (1997) (299)
Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. (1999) (297)
The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. (1997) (294)
Association of HbA1c With Prevalent Cardiovascular Disease in the Original Cohort of the Framingham Heart Study (1992) (294)
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. (2013) (286)
Acetaminophen and other risk factors for excessive warfarin anticoagulation (1998) (282)
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial (2014) (281)
Dipyridamole-thallium scanning in patients undergoing vascular surgery. Optimizing preoperative evaluation of cardiac risk. (1987) (270)
The effect of enforcing tobacco-sales laws on adolescents' access to tobacco and smoking behavior. (1997) (267)
Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. (1998) (261)
Recent national patterns of warfarin use in atrial fibrillation. (1998) (253)
Patients with syncope admitted to medical intensive care units. (1982) (251)
Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation (2011) (250)
Stroke Following Coronary-Artery Bypass Surgery (1988) (248)
Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study (2006) (244)
Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. (1990) (242)
Rationing intensive care--physician responses to a resource shortage. (1983) (239)
National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. (2004) (238)
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial (2013) (231)
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. (2003) (231)
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. (2015) (225)
National patterns of warfarin use in atrial fibrillation. (1996) (223)
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. (2000) (217)
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). (2014) (215)
Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. (2000) (205)
Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus (2002) (204)
Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. (2000) (200)
Screening for Diabetic Retinopathy (1992) (199)
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. (2002) (198)
Determinants of compliance with anticoagulation: A case-control study. (1997) (197)
Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. (2000) (191)
Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation (2010) (189)
Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. (1997) (187)
The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. (2001) (185)
Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. (1993) (183)
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial (2014) (177)
Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (2014) (173)
Evaluating area-based socioeconomic status indicators for monitoring disparities within health care systems: results from a primary care network. (2015) (172)
Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? (1999) (170)
Incidence of Newly Detected Atrial Arrhythmias via Implantable Devices in Patients With a History of Thromboembolic Events (2010) (167)
The Impact of Long-term Warfarin Therapy on Quality of Life: Evidence From a Randomized Trial (1991) (163)
Atrial Fibrillation Burden and Short-Term Risk of Stroke: Case-Crossover Analysis of Continuously Recorded Heart Rhythm From Cardiac Electronic Implanted Devices (2015) (162)
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. (2014) (162)
Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. (2012) (159)
Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. (2015) (158)
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. (2015) (157)
Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. (1996) (156)
Prognosis of patients hospitalized with community-acquired pneumonia. (1990) (153)
Retinopathy in Older Type II Diabetics Association With Glucose Control (1986) (153)
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2014) (152)
Bupropion for smokers hospitalized with acute cardiovascular disease. (2006) (151)
Diabetic Myocardial Infarction: Interaction of Diabetes With Other Preinfarction Risk Factors (1989) (149)
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? (1996) (148)
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial (2014) (144)
Efficacy of a smoking cessation program for hospital patients. (1997) (143)
The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. (1997) (142)
Acetaminophen and other risk factors for excessive warfarin anticoagulation. (1998) (140)
Tests of glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment. (1989) (138)
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) (2018) (136)
Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. (1997) (131)
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationClinical Perspective (2013) (130)
Tobacco-, alcohol-, and drug-attributable deaths and their contribution to mortality disparities in a cohort of homeless adults in Boston. (2015) (130)
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF (2015) (127)
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation (2016) (127)
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. (1991) (127)
Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. (1991) (126)
The relation between expectations and outcomes in surgery for sciatica (1999) (125)
Sustained care intervention and postdischarge smoking cessation among hospitalized adults: a randomized clinical trial. (2014) (119)
Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study (2009) (117)
Impact of concurrent medication use on statin adherence and refill persistence. (2004) (116)
Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. (2001) (115)
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). (2015) (112)
Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. (2003) (112)
Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. (2002) (109)
Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. (1998) (109)
Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (2013) (108)
Smoking by patients in a smoke-free hospital: prevalence, predictors, and implications. (2000) (108)
Relationship between rates and outcomes of operative treatment for lumbar disc herniation and spinal stenosis. (1999) (107)
Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (106)
Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation: Insights From ROCKET AF (2013) (106)
Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality. (2019) (104)
Trends in complexity of diabetes care in the United States from 1991 to 2000. (2004) (103)
Antithrombotic therapy in atrial fibrillation. (1998) (101)
Food Insufficiency and Health Services Utilization in a National Sample of Homeless Adults (2011) (101)
Antithrombotic therapy in atrial fibrillation. (2001) (101)
Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial (2014) (99)
Glycemic control in diabetes mellitus: have changes in therapy made a difference? (1996) (98)
Measuring symptomatic and functional recovery in patients with community-acquired pneumonia (1997) (98)
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2013) (98)
Improving Adherence and Reducing Medication Discrepancies in Patients with Diabetes (2003) (94)
Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits. (1988) (93)
National trends in the use of antibiotics by primary care physicians for adult patients with cough. (1998) (93)
Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. (2017) (92)
Screening for Ovarian Cancer (1994) (92)
Depressive symptom burden as a barrier to screening for breast and cervical cancers. (2004) (91)
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (2018) (89)
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis (2017) (89)
Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. (1996) (87)
Differences in length of hospital stay in patients with community-acquired pneumonia: a prospective four-hospital study. (1993) (86)
Desire for antibiotics and antibiotic prescribing for adults with upper respiratory tract infections (2003) (86)
Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. (1995) (83)
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. (2014) (83)
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. (2013) (83)
Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (82)
Dipyridamole-Thallium Scanning in Patients Undergoing Vascular Surgery-Reply (1987) (81)
The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. (1992) (81)
The Impact of Disability Compensation on Long-term Treatment Outcomes of Patients With Sciatica Due to a Lumbar Disc Herniation (2006) (81)
Non-insulin-dependent diabetes in older patients. Complications and risk factors. (1986) (80)
Digoxin and Risk of Death in Adults With Atrial Fibrillation: The ATRIA-CVRN Study (2013) (80)
Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia (1995) (79)
Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. (2016) (79)
Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. (1998) (78)
Association between antibiotic prescribing and visit duration in adults with upper respiratory tract infections. (2003) (78)
Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation (2017) (77)
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. (2009) (76)
Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2014) (74)
The uses of outcomes research for medical effectiveness, quality of care, and reimbursement in type II diabetes. (1994) (72)
Novel oral anticoagulants and reversal agents: Considerations for clinical development. (2015) (71)
Thirty-Day Mortality After Ischemic Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation On and Off Anticoagulants (2012) (71)
Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. (2016) (70)
Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. (2003) (70)
Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia (2000) (69)
Quantifying the potential benefit of CA 125 screening for ovarian cancer. (1991) (68)
A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP). (2004) (67)
Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. (2014) (67)
Are patients more likely to see physicians of the same sex? Recent national trends in primary care medicine. (2004) (64)
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF (2018) (64)
Protecting an Endangered Species: Training Physicians to Conduct Clinical Research (2009) (64)
Cocaine-related symptoms in patients presenting to an urban emergency department. (1991) (63)
Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy (2013) (61)
Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia (2001) (60)
Anticoagulation for atrial fibrillation. (2004) (57)
Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new‐onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT‐AF II) (2017) (56)
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. (2014) (56)
Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study (2017) (55)
The Maine-Seattle Back Questionnaire: A 12-Item Disability Questionnaire for Evaluating Patients with Lumbar Sciatica or Stenosis: Results of a Derivation and Validation Cohort Analysis (2003) (55)
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (2017) (55)
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. (2016) (52)
Randomized trials of warfarin for atrial fibrillation. (1992) (52)
Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke (2017) (51)
Community‐Acquired Pneumonia and Do Not Resuscitate Orders (2002) (50)
Time course of symptom resolution in patients with community-acquired pneumonia. (1998) (50)
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. (2016) (50)
Abstract 148: Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial (2012) (49)
Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. (1993) (48)
Health Literacy and Awareness of Atrial Fibrillation (2017) (48)
The use of nicotine-replacement therapy by hospitalized smokers. (1999) (47)
Disparities in Cancer Incidence, Stage, and Mortality at Boston Health Care for the Homeless Program. (2015) (46)
Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. (2002) (46)
End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience (2013) (46)
Hospitalization decision in febrile intravenous drug users. (1990) (45)
Development and validation of a new health-related quality of life instrument for patients with sinusitis (2005) (45)
Health-related quality of life of adults with upper respiratory tract infections (2003) (44)
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. (2014) (44)
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. (2019) (43)
Factor V Leiden and Risk of Ischemic Stroke in Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2003) (41)
Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. (2016) (41)
Rationale and Design of a Large Population Study to Validate Software for the Assessment of Atrial Fibrillation from Data Acquired by a Consumer Tracker or Smartwatch: The Fitbit Heart Study. (2021) (41)
Long-term survival after ischemic stroke in patients with atrial fibrillation (2014) (41)
Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial (2012) (40)
A Post-Discharge Smoking-Cessation Intervention for Hospital Patients: Helping Hand 2 Randomized Clinical Trial. (2016) (40)
Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: The TRENDS study (2006) (39)
Measures of health-related quality of life for adults with acute sinusitis (2003) (38)
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice (2017) (38)
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (2016) (38)
Smoking cessation following admission to a coronary care unit (1991) (38)
Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. (2000) (38)
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) (2017) (37)
Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry (2013) (36)
Left ventricular ejection fraction. Physician estimates compared with gated blood pool scan measurements. (1988) (36)
Unexpected readmissions to the coronary-care unit during recovery from acute myocardial infarction. (1981) (36)
Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data. (2005) (36)
Preventing stroke in atrial fibrillation. (1997) (36)
Rate control and sinus rhythm maintenance in atrial fibrillation: national trends in medication use, 1980-1996. (1998) (36)
Screening for diabetes mellitus. (1988) (35)
Association of E-Cigarette Use With Smoking Cessation Among Smokers Who Plan to Quit After a Hospitalization (2018) (34)
Cigarette Smoking and Risk Perceptions During the COVID-19 Pandemic Reported by Recently Hospitalized Participants in a Smoking Cessation Trial (2021) (33)
Single-chamber and dual-chamber cardiac pacemakers. A formal cost comparison. (1986) (33)
First Diagnosis of Atrial Fibrillation at the Time of Stroke (2017) (31)
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). (2017) (31)
Risk factors for medication non-adherence among atrial fibrillation patients (2019) (30)
Community-acquired pneumonia due to Escherichia coli. (1998) (29)
Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke. (2021) (29)
Application of outcomes research in occupational low back pain: the Maine Lumbar Spine Study. (1996) (29)
Change in physician knowledge and attitudes after implementation of a pneumonia practice guideline (1999) (29)
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF (2016) (29)
Complications after overdose with tricyclic antidepressants (1985) (29)
Angiosarcoma of the heart: three-year survival and follow-up by nuclear magnetic resonance imaging. (1988) (29)
Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. (2021) (29)
Limited English Proficient Patients and Time Spent in Therapeutic Range in a Warfarin Anticoagulation Clinic (2013) (28)
Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants. (2017) (27)
Incidence and Outcomes of Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial (2012) (27)
Initial Precipitants and Recurrence of Atrial Fibrillation (2020) (26)
Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. (2019) (25)
Overview of the randomized trials to prevent stroke in atrial fibrillation. (1993) (25)
Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. (1998) (25)
Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study (2018) (25)
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. (2017) (24)
Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research (2017) (24)
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. (2017) (24)
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation (2018) (24)
Examining the Impact of Real-World Evidence on Medical Product Development (2017) (23)
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. (2016) (23)
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation (2018) (23)
Effect of Low‐Intensity Warfarin Anticoagulation on Level of Activity of the Hemostatic System in Patients With Atrial Fibrillation (1993) (23)
Disease understanding in patients newly diagnosed with atrial fibrillation (2017) (22)
Stability of High‐Quality Warfarin Anticoagulation in a Community‐Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2016) (22)
Prediction Score for Anticoagulation Control Quality Among Older Adults (2017) (22)
Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. (2012) (22)
Interactive Voice Response Calls to Promote Smoking Cessation after Hospital Discharge: Pooled Analysis of Two Randomized Clinical Trials (2017) (22)
Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2012) (20)
Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation (2018) (19)
Comparative effectiveness of post-discharge interventions for hospitalized smokers: study protocol for a randomized controlled trial (2012) (19)
Can Text Messages Improve Attendance to Primary Care Appointments in Underserved Populations? (2016) (19)
Anticoagulation Therapy for Patients with Non-Valvular Atrial Fibrillation (2012) (19)
Association of Intracranial Hemorrhage Risk With Non–Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis (2018) (19)
Patients with atrial fibrillation at low risk of stroke. (1998) (19)
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. (2019) (18)
Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. (1995) (18)
USE AND OUTCOMES OF ANTIARRHYTHMIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING ORAL ANTICOAGULATION: RESULTS FROM THE ROCKET AF TRIAL (2014) (18)
Health care resource utilization associated with a diabetes center and a general medicine clinic (2007) (18)
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. (2020) (17)
Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial. (2019) (17)
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation (2018) (17)
Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). (2015) (17)
The triage decision in pulmonary edema (1988) (16)
Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis (2007) (16)
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF (2018) (16)
Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS) (2019) (16)
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial (2015) (16)
Comparative effectiveness of post-discharge strategies for hospitalized smokers: study protocol for the Helping HAND 2 randomized controlled trial (2015) (16)
Adding rigor to stroke risk prediction in atrial fibrillation. (2015) (15)
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate (2016) (15)
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2018) (15)
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. (2017) (14)
Risk of Ischemic Stroke and Major Bleeding in Patients With Atrial Fibrillation and Cancer. (2019) (14)
Stroke prevention in atrial fibrillation (1997) (14)
Disparities in Quality of Primary Care by Resident and Staff Physicians: Is There a Conflict Between Training and Equity? (2019) (14)
Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial (2012) (13)
Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance Database (2017) (13)
Antithrombotic therapy in atrial fibrillation. (2001) (13)
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2016) (12)
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial (2016) (12)
Factors influencing left atrial volume in a population with preserved ejection fraction: Left ventricular diastolic dysfunction or clinical factors? (2016) (12)
How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? (2016) (12)
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (2017) (12)
Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA (2019) (12)
Antithrombotic therapy for stroke prevention in atrial fibrillation. (2005) (11)
Putting risk prediction in atrial fibrillation into perspective. (2012) (11)
Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. (2020) (11)
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation (2020) (10)
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. (2018) (10)
A 60-year-old woman with atrial fibrillation. (2003) (10)
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes (2016) (10)
What is the optimal anticoagulation intensity to prevent stroke in patients with atrial fibrillation >=75 versus <75 years old? The anticoagulation and risk factors in atrial fibrillation (ATRIA) study (2002) (10)
Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry (2019) (10)
Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: the VITAL-AF Randomized Controlled Trial (2021) (10)
Targeted Minimum Loss-Based Estimation of Causal Effects in Right-Censored Survival Data with Time-Dependent Covariates: Warfarin, Stroke, and Death in Atrial Fibrillation (2013) (10)
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. (2019) (9)
CHA2DS2-VASc risk scheme: not ready for clinical use. (2010) (9)
Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in. (2003) (8)
Abstract 206: Projected Estimates of Prevalence and Annual Growth Rate of Atrial Fibrillation in the United States from a Dynamic Age-Period Progression Model (2012) (8)
Anticoagulation for atrial fibrillation: epidemiology informing a difficult clinical decision. (1996) (8)
Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study (2021) (8)
PAROXYSMAL ATRIAL FIBRILLATION POSES A LARGE BUT TRANSIENT INCREASE IN ISCHEMIC STROKE RISK: A CASE-CROSSOVER STUDY (2015) (8)
Comparison of Risk Stratiﬁcation Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation (2008) (8)
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries (2018) (8)
Improvements in health-related quality of life among smokers who quit after hospitalization. (2018) (8)
Observations from a multicentre study on the use of the sputum specimen in patients hospitalized with community-acquired pneumonia. (1999) (8)
Automated Electronic Phenotyping of Cardioembolic Stroke (2020) (8)
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. (2019) (8)
Profile of Patients Diagnosed with Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. (2020) (7)
Maine Lumbar Spine Study. (1997) (7)
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial (2016) (7)
Smoking Cessation After Hospital Discharge: Factors Associated With Abstinence (2018) (7)
Human Immunodeficiency Virus (HIV) Quality Indicators Are Similar Across HIV Care Delivery Models (2017) (7)
Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. (2019) (7)
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. (2019) (7)
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study (2021) (6)
Noninvasive testing of asymptomatic bilateral hilar adenopathy (1990) (6)
Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial (2011) (6)
Examining the effects of illicit drug use on tobacco cessation outcomes in the Helping HAND 2 randomized controlled trial. (2017) (6)
Stroke prevention in atrial fibrillation: another step sideways (2008) (5)
Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. (2019) (5)
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF (2018) (5)
THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF) (2017) (5)
A new era in stroke prevention for atrial fibrillation: comment on "current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation. (2012) (5)
The Use of Logistic Regression in Diagnostic and Prognostic Prediction in a Medical Intensive Care Unit (1980) (5)
Sunday, 26 August 2012 (2012) (5)
Comparative effectiveness of post-discharge strategies for hospitalized smokers: Study protocol for the Helping HAND 4 randomized controlled trial (2020) (5)
Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk (2018) (5)
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. (2016) (4)
CHA 2 DS 2 -VASc Risk Scheme (2010) (4)
Risk Factors for Stroke and Primary Prevention of Stroke in Atrial Fibrillation (2004) (4)
Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation – A microsimulation study (2018) (4)
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF (2019) (4)
Community-acquired pneumonia. (2014) (4)
Problems with stopping rules in the trials of risky therapies: the case of warfarin to prevent stroke in atrial fibrillation. (1993) (4)
Abstract 15686: Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke: Results From the ROCKET AF Trial (2014) (4)
Abstract 14365: Rivaroxaban is Associated with a Reduced Risk of Thromboembolic events and Hemorrhagic Stroke in Patient with Heart Failure: Insights from ROCKET AF (2012) (4)
Edinburgh Research Explorer Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation (2015) (4)
Outcomes of patients with atrial fibrillation and significant valvular lesions: Comparison of the effects of rivaroxaban and warfarin in the ROCKET AF trial (2013) (4)
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. (2019) (4)
Screening for HTLV-III Antibodies: The Relation Between Prevalence and Positive Predictive Value and Its Social Consequences (1985) (3)
Abstract 15879: Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial (2013) (3)
Usefulness of Rhythm Monitoring Following Acute Ischemic Stroke. (2021) (3)
THE MYTH OF THE STABLE INR PATIENT: RESULTS FROM ORBIT-AF (2015) (3)
The limited clinical value of home urine testing by diabetic patients (1986) (3)
OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL (2014) (3)
Screening for Diabetes (1990) (3)
Sociodemographic determinants in the hospitalization decision: evaluation of an emergency department interhospital transfer policy. (1993) (3)
Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF. (2021) (3)
Patterns of oral anticoagulation use with cardioversion in clinical practice (2020) (3)
Abstract 16443: Development of a New Risk Stratification Scheme to Predict Warfarin-Associated Hemorrhage: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study (2010) (3)
The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. (2009) (3)
ORAL ANTICOAGULANT SELECTION IN COMMUNITY PATIENTS WITH NEW-ONSET ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT-AF II REGISTRY (2016) (2)
Community-acquired pneumonia [1] (1996) (2)
Abstract 14870: Quality of Anticoagulation Management in Atrial Fibrillation and Venous Thromboembolism: The CVRN WAVE Study (2010) (2)
Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation (2019) (2)
Abstract 12682: Accuracy of Expert Electrocardiography versus ST-Segment Elevation Myocardial Infarction Criteria for Diagnosis of Acute Coronary Occlusion Myocardial Infarction (2020) (2)
Reply Comparing the ATRIA, CHADS2, and CHA2DS2-VASc Scores for Stroke Prediction in Atrial Fibrillation (2016) (2)
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL (2013) (2)
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation (2020) (2)
Patient And Physician Preferences In The United States For Benefits And Risks Of Anticoagulant Use In Atrial Fibrillation – Results From A Conjoint-Analysis Study (2013) (2)
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II) (2021) (2)
An Instrument for Determining the Amount of NIH Support for Clinical Investigations at One Academic Health Center (2002) (2)
Unrecognized History of Transient Atrial Fibrillation at the Time of Discharge from an Index Stroke Hospitalization Is Associated with Increased Recurrent Stroke Risk (2019) (2)
Medical Intensive Care Unit Admissions for Syncope-Reply (1983) (1)
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF (2021) (1)
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation (2022) (1)
Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice (2020) (1)
Systolic blood pressure as a prognostic factor in acute pulmonary edema (1989) (1)
The Course of Patients with Suspected Myocardial Infarction - Prediction of Complications Using a Computer-Based Databank (1980) (1)
P3849Baseline profile of patients treated for acute venous thromboembolism in routine clinical practice according to age and renal function in the RE-COVERY DVT/PE global cohort study (2019) (1)
Abstract 11900: Influence of Competing Risks on the Association Between Warfarin and Ischemic Stroke in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2015) (1)
Abstract 3590: Defining a Threshold of Anticoagulation Quality that Leads to Net Clinical Benefit in Atrial Fibrillation: The ATRIA Study (2007) (1)
Clopidogrel as Antithrombotic Therapy in Atrial Fibrillation (2005) (1)
Abstract 19336: Reported Stroke Rates in Patients With Nonvalvular Atrial Fibrillation in North America are Lower Than Those Cited in ESC and AHA Guidelines (2015) (1)
Preventing Stroke in Atrial Fibrillation: Overview of the Randomized Trials of Antithrombotic Therapy (1995) (1)
THE USE OF DUAL ANTIPLATELET THERAPY AND PATIENT OUTCOMES IN THOSE UNDERGOING PCI IN THE ROCKET AF TRIAL (2014) (1)
Abstract 207: VITAL-AF: A Pragmatic Trial Integrating Routine Screening for Atrial Fibrillation During Primary Care Visits (2019) (1)
Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation (2023) (1)
Comparison of ATRIA and CHA2DS2-VASc risk stratification schemes for the prediction of stroke in the individual patient with atrial fibrillation and the impact on treatment decisions (2014) (1)
Abstract 16840: Predictors of Hospitalization in Patients With Atrial Fibrillation: An Analysis From ROCKET AF (2014) (1)
Tests of glycemia. Authors' reply (2003) (1)
Abstract 215: Efficacy and Safety of Novel Oral Anticoagulants (NOACs) in Asian population with Non-Valvular Atrial Fibrillation (NVAF) - A Meta-Analysis (2015) (1)
Abstract 18832: The ORBIT-AF Bleeding Score: a Simple Score to Assess Major Bleeding Risk in Atrial Fibrillation (2014) (1)
Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage. (2020) (1)
Abstract 4: Variation in Published Stroke Rates Results in Wide Variation in the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation (2018) (1)
Preventive Cardiovascular/Metabolic Health Screening in an HIV+ Cohort by Type of Primary Care Model (2015) (1)
The limited clinical value of home urine testing by diabetic patients (2007) (1)
Independent Predictors of Mortality in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF (2012) (1)
Abstract 16785: Atrial Fibrillation Clinical Phenotypes: A Cluster Analysis (2017) (1)
Abstract 15956: Triple Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and History of Coronary Artery Disease: Insights From the ORBIT-AF Registry (2013) (0)
Abstract WP182: Perioperative Atrial Fibrillation Increased Risks of Stroke and Mortality: A Meta-Analysis (2018) (0)
Abstract 217: How well does the CHADS2 Stroke Risk Score Predict Major Hemorrhage in Patients with Atrial Fibrillation? (2013) (0)
Reply: Comparing the ATRIA, CHADS2, and CHA2DS2-VASc Scores for Stroke Prediction in Atrial Fibrillation. (2016) (0)
Abstract 18127: Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation (2017) (0)
Rhinosinusitis Quality of Life Survey (2018) (0)
Abstract W P309: Hemorrhagic Risk Associated with Warfarin Initiation among Patients with Atrial Fibrillation: Assessment via a Large Insurance Database (2014) (0)
Abstract 11: Selective Serotonin Reuptake Inhibitors Increase Major Hemorrhage Risk in Patients with Atrial Fibrillation Taking Warfarin (2012) (0)
Response to Letter by Willey (2010) (0)
Abstract 16467: Can a Model-Based Decision Support Tool Improve Anticoagulation Outcomes for Atrial Fibrillation? Results From a Large Database Cohort (2011) (0)
Abstract 156: Body Mass Index and Outcomes among Patients with Atrial Fibrillation from the ATRIA2-CVRN Study (2013) (0)
NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF) (2017) (0)
Adjusted Dose Vitamin-K Antagonist , Comparing Efficacy and Safety With Unadjusted (2008) (0)
Highlights From the Circulation Family of Journals. (2020) (0)
Supplementary Material for: First Diagnosis of Atrial Fibrillation at the Time of Stroke (2017) (0)
Abstract TMP90: Limited Use of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation After Ischemic Stroke (2016) (0)
Risk of stroke from carotid bruits. (1989) (0)
Abstract 192: Comparative Clinical Effectiveness of Population-based Atrial Fibrillation Screening Using Wearable Devices: A Decision-Analytic Model (2020) (0)
COST-EFFECTIVENESS OF EXTENDED AND ONE-TIME SCREENING FOR ATRIAL FIBRILLATION VERSUS NO SCREENING IN THE UNITED STATES (2018) (0)
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). (2020) (0)
The Analysis of Bleeding Risk–Prediction Scores Should Include All Major Bleeds (2013) (0)
Abstract TP394: Comparison of Major Bleeding Endpoints Between Non-vitamin K Antagonist Oral Anticoagulants and Aspirin: A Network Meta-Analysis (2018) (0)
Abstract 15083: Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2016) (0)
Tests of Glycemia in Diabetes Mellitus (2020) (0)
36 for Diabetes Mellitus (1990) (0)
Anticoagulation Initiative Overview (2009) (0)
Tobacco-,Alcohol-,andDrug-AttributableDeathsand TheirContributiontoMortalityDisparitiesinaCohort ofHomelessAdultsinBoston (2015) (0)
Tests of Glycemia (2003) (0)
THE IMPACT OF TEMPORARY INTERRUPTIONS OF WARFARIN ON DOWNSTREAM TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM ORBIT AF (2019) (0)
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". (2016) (0)
Reply: Recent Diabetes and Atrial Fibrillation Report Diverges From Pre-Existing Evidence. (2016) (0)
A RANDOMIZED CLINICAL TRIAL OF SCREENING FOR ATRIAL FIBRILLATION WITH A 14-DAY PATCH MONITOR: ANALYSIS OF ECG RECORDINGS FROM THE GUARD-AF STUDY (2022) (0)
Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial (2014) (0)
Atrial Fibrillation and the Risk of Intracranial Hemorrhage: Predictors and Risk Assessment (2010) (0)
Abstract 13727: Contemporary Rates and Correlates of Warfarin Use in 33,570 Adults with Atrial Fibrillation: The ATRIA2-CVRN Study (2010) (0)
Warfarin or Not Warfarin (2005) (0)
Efficacy of Long-term Antithrombotic Therapy in AF Study (2001) (0)
Comparison of Long-Term Risk Adverse Outcomes In Patients with Atrial Fibrillation Having Ablation vs Antiarrhythmic Medications (2020) (0)
Concern About Anthrax Among Adults With Respiratory Illnesses (2002) (0)
1153-72 Depression in smokers hospitalized with acute cardiovascular disease increases nicotine withdrawal symptoms and early relapse to smoking (2004) (0)
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial (2021) (0)
Abstract 16902: Efficacy and Safety of Rivaroxaban versus Warfarin in Patients Taking Non-dihydropyridine Calcium Channel Blockers: Results From the ROCKET AF Trial (2015) (0)
Abstract 16169: Individual and Regional Determinants of Time in Therapeutic Range Among Patients Randomized to Warfarin in the ROCKET AF Trial of Rivaroxaban (2011) (0)
CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRY (2019) (0)
Clopidogrel as antithrombotic therapy in atrial fibrillation. Author's reply (2005) (0)
Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation (2019) (0)
Abstract WP303: Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The ATRIA Study (2016) (0)
Impact of Perioperative Tranexamic Acid on Risk of Bleeding in Total Hip and Knee Arthroplasty: An Analysis of the Epcat II Data (2018) (0)
P3622Timing of trial stoppage for non-inferiority trials and interpretation: lessons from ROCKET AF (2017) (0)
Abstract 18538: The ATRIA Stroke Risk Score Predicts Ischemic Stroke Better than CHADS2 and CHA2DS2-VASc in a large Swedish Cohort of Patients with Atrial Fibrillation (2014) (0)
tive,randomizedclinicaltrialisneededtoestablishthevalue of determining thrombomodulin level in clinical practice. (2017) (0)
Abstract 3589: Warfarin Therapy, Anticoagulation Intensity and Outcomes in Older vs. Younger Patients with Atrial Fibrillation: The ATRIA Study (2007) (0)
Correction to: Comparative effectiveness of post-discharge strategies for hospitalized smokers: Study protocol for the Helping HAND 4 randomized controlled trial (2020) (0)
Abstract 325: Paradoxical Relationship Between Bleeding Risk, Stroke Risk, and Time in Therapeutic Range for Atrial Fibrillation Patients on Warfarin: Data from ORBIT-AF (2014) (0)
P3848Baseline profile of patients treated for acute venous thromboembolism (VTE) in routine clinical practice according to VTE location in the RE-COVERY DVT/PE global cohort study (2019) (0)
TREATMENT AND STROKE RISK IN LOW RISK CHA2DS2VASC ATRIAL FIBRILLATION PATIENTS: FINDINGS FROM THE ORBIT-AF REGISTRY (2016) (0)
ASSESSMENT OF STROKE RISK IN ATRIAL FIBRILLATION: PHYSICIAN ESTIMATE VERSUS CHADS2 RISK SCORE: RESULTS FROM ORBIT-AF (2014) (0)
EFFICACY AND SAFETY OF DABIGATRAN ETEXILATE VERSUS VITAMIN K ANTAGONIST FOR TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN ROUTINE CLINICAL PRACTICE: RECOVERY DVT/PE PROSPECTIVE GLOBAL COHORT STUDY (2020) (0)
Practice Guidelines Chest Physicians Evidence-Based Clinical Thrombosis, 9th ed: American College of : Antithrombotic Therapy and Prevention of Antithrombotic Therapy for Atrial Fibrillation (2012) (0)
P6344Pulmonary embolism is a possible risk factor for ischemic stroke before 65 years of age in patients with atrial fibrillation (2018) (0)
Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2013) (0)
FORECASTING TRENDS IN CARDIOMETABOLIC RISK FACTORS IN THE UNITED STATES: ESTIMATES BASED ON THE 2020 CENSUS (2022) (0)
Abstract P185: Self-Reported Medication Adherence in 14,246 Patients with Atrial Fibrillation from the ATRIA2-CVRN Study (2011) (0)
Acetaminophen and risk factors for excess anticoagulation with warfarin. (1998) (0)
Abstract WP302: Atrial Fibrillation First Diagnosed at the Time of Ischemic Stroke: A Missed Opportunity (2016) (0)
Abstract 11999: External Validation of a New Risk Score to Predict Stroke in Atrial Fibrillation (2012) (0)
Creatine kinase levels among asymptomatic patients with severe mental illnesses: A complex baseline for an important clinical biomarker (2021) (0)
CENTRAL ILLUSTRATION Assessing Which Characteristics of Diabetes Are Associated With Ischemic Stroke in Patients With Atrial Fibrillation Increased duration of diabetes Potential mechanisms : Enhanced thrombin generation Impaired fibrinolysis with prolonged lysis time Patient with atrial fibrillatio (2016) (0)
Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study (2020) (0)
Abstract 17226: Latin American Patients With Atrial Fibrillation Have a Higher Risk Profile but Similar Response With Rivaroxaban versus Warfarin: A ROCKET AF Substudy (2017) (0)
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE (2017) (0)
Abstract 186: A New Risk Model to Predict Stroke in Atrial Fibrillation (2012) (0)
ASSOCIATION BETWEEN GUIDELINE-DIRECTED MEDICAL THERAPIES FOR COMORBID CONDITIONS AND CLINICAL OUTCOMES AMONG INDIVIDUALS WITH ATRIAL FIBRILLATION (2019) (0)
Anticoaeulation for atrial fibrillation (2004) (0)
Maine lumbar spine study. (1997) (0)
Warfarin or not warfarin? Commentary (2005) (0)
Évaluation de l'intensité minimale efficace du traitement anticoagulant prophylactique au cours de la fibrillation auriculaire non rhumatismale (1996) (0)
Single-Chamber and Dual-Chamber Cardiac Pacemakers (2020) (0)
Wednesday, 29 August 2012 (2012) (0)
Journal Pre-proof Residual Stroke Risk Despite Oral Anticoagulation in Patients with Atrial Fibrillation (2022) (0)
Abstract 13006: High Use of Concomitant Antiplatelet Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2012) (0)
Abstract 4580: Proteinuria and Reduced Glomerular Filtration Rate Independently Increase Risk of Thromboembolism in Atrial Fibrillation: The ATRIA Study (2008) (0)
NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY (2019) (0)
Chapter 15 – Anticoagulant and Antiplatelet Drug Therapy in Atrial Fibrillation (2004) (0)
Abstract P226: Anticoagulation Therapy for Patients with Nonvalvular Atrial Fibrillation: Comparison of Decision Analytic Model Recommendation and Real-World Warfarin Prescription Use (2011) (0)
Options for health and health care: The coming of post- clinical medicine: by Alfred E. Miller and Maria G. Miller. Wiley, New York. 1981. 478 pp. (1982) (0)
Abstract 14586: Anxiety but Not Depression Influences Risk of Stroke in Adults With Atrial Fibrillation: CVRN WAVE Study (2017) (0)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation the Investigators* (0)
Abstract 17137: Renal Dysfunction is a Potent Predictor of Stroke and Systemic Embolism Among Individuals with Atrial Fibrillation: Results from the ROCKET AF Trial (2011) (0)
Abstract 078: Implications of Patient-Reported Treatment Satisfaction for Discontinuation of Rivaroxaban versus Warfarin in ROCKET-AF (2017) (0)
The cultural crisis of modern medicine: John Ehrenreich. Monthly Review, NY, 1978. 300 pp. $5.95 (1981) (0)
Association of Kidney Function With Risk of Adverse Effects of Therapies for Atrial Fibrillation (2022) (0)
Abstract 127: Differences in Care Patterns, Health Status, and Outcomes of Atrial Fibrillation in Patients With and Without Diabetes: Findings From the ORBIT-AF Registry (2017) (0)
FUTURE OF CARDIOVASCULAR DISEASE IN THE UNITED STATES: ESTIMATES BASED ON THE 2020 CENSUS (2022) (0)
ASSOCIATION BETWEEN ELEVATED B-TYPE NATRIURETIC PEPTIDE, DISEASE PROGRESSION, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Daniel E. Singer?

Daniel E. Singer is affiliated with the following schools: